Image pharmaphorum Editor News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial. Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP). Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer. News Hepatitis drug wins award for cure rate and efficacy Hepatitis C drug Ganovo won a top clinical research award due to its successful performance in a phase 3 trial. Load more results
News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial.
Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer.
News Hepatitis drug wins award for cure rate and efficacy Hepatitis C drug Ganovo won a top clinical research award due to its successful performance in a phase 3 trial.
News MSD splits pharma business, hiving off oncology MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
